Opher Gileadi obtained his PhD in Biochemistry at the Hebrew University and was then a postdoctoral fellow at Stanford University Medical School. Subsequently he led a research group at the Weizmann Institute of Science. From 2004-2021 he was both at SGC University of Oxford, first as head of the Biotechnology group, then as Principal Investigator of the Genome Integrity & Repair Group as well as Head of the SGC Kinase Chemical Biology Center at the State University of Campinas (UNICAMP). In 2021 Opher took at position as Executive Director, Protein Science and Structure at Exscientia, but re-join the SGC at Karolinska in 2023.
Opher leads the Protein Science team at SGC Karolinska, focussing on developing antibodies and target-enabling packages (TEPs) for under-investigated proteins of humans and pathogens.
Burgess-Brown NA, Sharma S, Sobott F, Loenarz C, Oppermann U, Gileadi O
Protein Expr. Purif.. 2008-1-26 . 59(1):94-102 .doi: 10.1016/j.pep.2008.01.008
PMID: 18289875Gileadi O, Knapp S, Lee WH, Marsden BD, Müller S, Niesen FH, Kavanagh KL, Ball LJ, von Delft F, Doyle DA, Oppermann UC, Sundström M
J. Struct. Funct. Genomics. 2007-10-12 . 8(2-3):107-19 .doi: 10.1007/s10969-007-9027-2
PMID: 17932789Ng SS, Kavanagh KL, McDonough MA, Butler D, Pilka ES, Lienard BM, Bray JE, Savitsky P, Gileadi O, von Delft F, Rose NR, Offer J, Scheinost JC, Borowski T, Sundstrom M, Schofield CJ, Oppermann U
Nature. 2007-7-5 . 448(7149):87-91 .doi: 10.1038/nature05971
PMID: 17589501Johansson C, Kavanagh KL, Gileadi O, Oppermann U
J. Biol. Chem.. 2007-2-2 . 282(5):3077-82 .doi: 10.1074/jbc.M608179200
PMID: 17121859